HER-2阳性晚期乳腺癌治疗策略  

Therapeutic strategy for HER-2-positive advanced breast cancer

作　　者：孙婧[1] 张频[1] 

机构地区：[1]中国医学科学院肿瘤医院肿瘤内科,北京市100021

出　　处：《中国肿瘤临床》2016年第10期412-417,共6页Chinese Journal of Clinical Oncology

摘　　要：HER-2阳性晚期乳腺癌患者预后差,以抗HER-2靶向治疗为基础的综合治疗显著延长了患者的生存期、改善了预后。目前多种抗HER-2靶向药物已应用于临床,抑制HER-2通路是HER-2阳性晚期乳腺癌患者一线治疗及一线治疗进展后的基础治疗。本文简要介绍HER-2阳性晚期乳腺癌治疗相关的关键临床研究、指南推荐及今后的研究方向,以指导临床实践。Patients with HER-2-positive advanced breast cancer were associated with poor prognosis. Meanwhile, HER-2-targeted ther- apy has dramatically improved survival and prognosis among breast cancer patients. Over the years, multiple HER-2-targeting drugs stepped into clinical practice, and the targeted agents are now considered as the standard of care in the first-line setting and beyond. This review basically summarizes the importance of HER-2-targeted therapy, the significance of the clinical trial results, and the clinical practice guidelines for the management of patients with HER-2-positive advanced breast cancer.

关 键 词：HER-2阳性 晚期乳腺癌 治疗策略 临床研究 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]